Testosterone News and Research

Latest Testosterone News and Research

Testosterone and body fat are controlled by the same genes

Genes that control percentage of body fat are also responsible for circulating levels of testosterone in men, research published in the latest edition of Clinical Endocrinology shows. The research shows a 23% overlap between the genes that control testosterone and those that regulate body fat composition, suggesting that these two variables are partly controlled by the same set of genes.

4 Aug 2008

Hormone deprivation therapy - used for prostate cancer - may cause recall and concentration problems

A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients--such as in the ability to recall and concentrate.

28 Jul 2008

Abiraterone new drug for aggressive prostate cancer the best thing in 70 years

Scientists say a new drug which treats aggressive prostate cancer is possibly the most significant development in the field for 70 years.

22 Jul 2008

Gene change sheds light on sex development disorder

One in 4,500 people suffer from a group of conditions known as sex development disorders (DSD) which occur when the sex chromosomes do not match the genitalia.

7 Jul 2008

Pregnancy may protect against bladder cancer

Female mice that had never become pregnant had approximately 15 times as much cancer in their bladders as their counterparts that had become pregnant, according to new findings by investigators at the University of Rochester Medical Center. Their work appears online as a rapid communication in the journal Urology.

26 Jun 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

Many men with androgen deficiency do not receive treatment

The majority of men with androgen deficiency may not be receiving treatment despite having sufficient access to care, according to a report in the May 26 issue of Archives of Internal Medicine.

26 May 2008

Study finds increased risk of some cancers among HIV-positive people in U.S.

HIV-positive people in the U.S., many of whom are living longer because of antiretroviral drugs, are at an increased risk for certain types of cancers, according to a study published Tuesday in the Annals of Internal Medicine, Reuters reports.

22 May 2008

Oestrogen works for women the way testosterone does for men

Collaboration by American and German scientists has revealed that the sex hormone oestrogen increases a women's competitiveness.

5 May 2008

MacroChem acquires Virium Pharmaceuticals

MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.

23 Apr 2008

Developmental changes during the teenage years raise men's heart disease risk

Normal developmental changes during the teenage years leave young adult men at higher risk of heart disease than their female counterparts, researchers report in Circulation: Journal of the American Heart Association.

21 Apr 2008

Five-alpha-reductase Inhibitors for prostate cancer prevention

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5-9% to around 4-6% during up to 7 years of treatment, according to a new Cochrane Review.

17 Apr 2008

Menstrual status and long-term cardiovascular effects of intense exercise in top elite athlete women’

It has long been assumed that menstrual disorders amongst elite female athletes are related to tough training regimes combined with insufficient energy intake. However, a new doctoral thesis from the Swedish medical university Karolinska Institutet overturns old ideas that elite sport can damage the health. Many elite female athletes can have a congenital condition, that gives them higher levels of testosterone and that might even contribute to their sporting successes.

17 Apr 2008

How hormone levels affect financial traders

When City traders have high morning testosterone levels they make more than average profits for the rest of that day, researchers at the University of Cambridge have discovered.

15 Apr 2008

Lipitor and Celebrex combined may halt prostate cancer

Researchers at Rutgers' Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.

15 Apr 2008